<DOC>
	<DOCNO>NCT00767039</DOCNO>
	<brief_summary>Approval surfactant FDA 1989 treatment Respiratory Distress Syndrome ( RDS ) premature infant greatly improve survival rate . Newer surfactant approve FDA concentrate rapid onset action . The overall efficacy new surfactant appear similar 2004 , Ramanathan colleague suggest double dose Curosurf improve survival infant 25-32 week gestational age , compare infant treat Survanta , commonly use surfactant preparation United States . While data suggestive , clear improvement survival reproducible Curosurf responsible improve survival rate . The purpose study investigate role Curosurf improve lung function survival rate reduce complication prematurity premature infant &lt; 30 week gestational age birth .</brief_summary>
	<brief_title>Curosurf Survanta Treatment ( CAST ) RDS Very Premature Infants</brief_title>
	<detailed_description>Specific Aims : - To determine whether sustained difference level respiratory support first 3 day life extremely premature infant treat Curosurf versus Survanta - To determine whether Curosurf associate high incidence hemodynamically significant PDA , compare Survanta - To determine whether difference cerebral blood flow response Curosurf versus Survanta - To determine whether difference morbidity premature infant treat Curosurf versus Survanta We reason Curosurf primarily responsible improve survival rate , compare Survanta , sustain improvement respiratory function first three day life , direct pulmonary effect surfactant preparation would easily detect . It also possible Curosurf Survanta could effect system could secondarily affect long-term survival infant . These organ system would include , limited , development hemodynamically significant Patent Ductus Arteriosus , Intraventricular Hemorrhage Periventricular Leukomalacia , Necrotizing Enterocolitis . We propose examine surfactant administration affect hemodynamic precursor common morbidity premature infant .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<mesh_term>Poractant alfa</mesh_term>
	<mesh_term>Pulmonary Surfactants</mesh_term>
	<mesh_term>Beractant</mesh_term>
	<criteria>&lt; 29 6/7 &gt; 24 0/7 week gestational age Inborn participate institution enrol patient FIO2 &gt; 25 % Intubated mean airway pressure &gt; 5 cm H20 &lt; 8 hour age randomization Signed informed consent parent ( ) &lt; 500 g birth weight &lt; 24 0/7 week gestational age ( best estimate ) Prolonged Premature Rupture membranes &gt; 3 week ( 21 day ) Apgar score &lt; 3 5 minute Impending death anticipate within first 3 day life , moribund Severe congenital anomaly</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>8 Hours</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Very Premature</keyword>
	<keyword>RDS</keyword>
	<keyword>Surfactant</keyword>
</DOC>